[go: up one dir, main page]

PE20011066A1 - PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS - Google Patents

PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS

Info

Publication number
PE20011066A1
PE20011066A1 PE2001000072A PE2001000072A PE20011066A1 PE 20011066 A1 PE20011066 A1 PE 20011066A1 PE 2001000072 A PE2001000072 A PE 2001000072A PE 2001000072 A PE2001000072 A PE 2001000072A PE 20011066 A1 PE20011066 A1 PE 20011066A1
Authority
PE
Peru
Prior art keywords
pyrimidin
cyane
nr9r10
halo
pyrid
Prior art date
Application number
PE2001000072A
Other languages
English (en)
Spanish (es)
Inventor
Richard John Booth
Ellen Myra Dobrusin
Peter Laurence Toogood
Dennis Joseph Mcnamara
Vara Prasad Venkata Nagendra Josyula
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20011066A1 publication Critical patent/PE20011066A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
PE2001000072A 2000-01-25 2001-01-23 PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS PE20011066A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17826100P 2000-01-25 2000-01-25

Publications (1)

Publication Number Publication Date
PE20011066A1 true PE20011066A1 (es) 2001-10-22

Family

ID=22651853

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000072A PE20011066A1 (es) 2000-01-25 2001-01-23 PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS

Country Status (34)

Country Link
EP (1) EP1254137A1 (et)
JP (1) JP4047010B2 (et)
KR (1) KR20020065939A (et)
CN (1) CN1395578A (et)
AP (1) AP2002002586A0 (et)
AR (1) AR030044A1 (et)
AU (1) AU2542501A (et)
BG (1) BG106850A (et)
BR (1) BR0107751A (et)
CA (1) CA2397961C (et)
CO (1) CO5261549A1 (et)
CR (1) CR6706A (et)
CZ (1) CZ20022475A3 (et)
DZ (1) DZ3266A1 (et)
EA (1) EA200200643A1 (et)
EE (1) EE200200405A (et)
GT (1) GT200100016A (et)
HN (1) HN2001000013A (et)
HU (1) HUP0204141A3 (et)
IL (1) IL150545A0 (et)
IS (1) IS6443A (et)
MA (1) MA26868A1 (et)
MX (1) MXPA02007221A (et)
NO (1) NO20023527L (et)
OA (1) OA12161A (et)
PA (1) PA8510701A1 (et)
PE (1) PE20011066A1 (et)
PL (1) PL356802A1 (et)
SK (1) SK10632002A3 (et)
SV (1) SV2002000294A (et)
TN (1) TNSN01014A1 (et)
WO (1) WO2001055147A1 (et)
YU (1) YU50402A (et)
ZA (1) ZA200205879B (et)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
WO2002059083A2 (en) 2000-10-23 2002-08-01 Smithkline Beecham Corporation Novel compounds
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
JP4603268B2 (ja) 2002-04-19 2010-12-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規化合物
RS20050363A (sr) * 2002-11-28 2007-11-15 Schering Aktiengesellschaft, Chk-,Pdk- I Akt-INHIBITORNI PIRIMIDINI, NJIHOVA PROIZVODNJA I UPOTREBA KAO FARMACEUTSKIH SREDSTAVA
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
TW200502236A (en) 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
CA2579406A1 (en) * 2004-09-21 2006-03-30 F.Hoffmann-La Roche Ag 6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as protein kinase inhibitors
UY29439A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
US20090137550A1 (en) 2005-03-25 2009-05-28 Glaxo Group Limited Novel Compounds
SG160438A1 (en) 2005-03-25 2010-04-29 Glaxo Group Ltd Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5- d]pyrimidin-2(1h)-one derivatives
PE20100737A1 (es) 2005-03-25 2010-11-27 Glaxo Group Ltd Nuevos compuestos
FR2887882B1 (fr) 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
CA2614443C (en) * 2005-07-21 2011-03-22 F. Hoffmann-La Roche Ag Pyrido [2,3-d] pyrimidine-2,4-diamine compounds as ptp1b inhibitors
BRPI0614804A2 (pt) 2005-08-09 2011-04-12 Irm Llc compostos e composições como inibidores de proteìna cinase
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
JP5697601B2 (ja) * 2008-12-01 2015-04-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 癌に対するオータキシン阻害剤としての2,5−ジアミノ−置換ピリド[4,3−d]ピリミジン
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
EP2968331B1 (en) * 2013-03-14 2020-07-01 Icahn School of Medicine at Mount Sinai Pyrimidine compounds as kinase inhibitors
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR101671404B1 (ko) * 2014-09-02 2016-11-02 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
CN107286180B (zh) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE190978T1 (de) * 1994-11-14 2000-04-15 Warner Lambert Co 6-aryl-pyrido(2,3-d)pyrimidine und -naphthyridine zur hemmung der durch protein-tyrosin-kinase hervorgerufenen zellvermehrung
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
KR20010043829A (ko) * 1998-05-26 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 비시클릭 피리미딘 및 비시클릭3,4-디히드로피리미딘

Also Published As

Publication number Publication date
CA2397961C (en) 2008-08-26
AU2542501A (en) 2001-08-07
NO20023527L (no) 2002-09-10
CA2397961A1 (en) 2001-08-02
YU50402A (sh) 2005-11-28
OA12161A (en) 2006-05-08
EP1254137A1 (en) 2002-11-06
CZ20022475A3 (cs) 2003-03-12
HUP0204141A3 (en) 2005-03-29
MA26868A1 (fr) 2004-12-20
TNSN01014A1 (fr) 2005-11-10
CR6706A (es) 2005-04-04
BG106850A (bg) 2003-02-28
JP2003523357A (ja) 2003-08-05
ZA200205879B (en) 2003-09-29
SV2002000294A (es) 2002-07-16
JP4047010B2 (ja) 2008-02-13
IL150545A0 (en) 2003-02-12
DZ3266A1 (fr) 2001-08-02
BR0107751A (pt) 2002-11-12
AR030044A1 (es) 2003-08-13
IS6443A (is) 2002-06-25
EA200200643A1 (ru) 2002-12-26
HUP0204141A2 (hu) 2003-04-28
MXPA02007221A (es) 2002-11-29
CO5261549A1 (es) 2003-03-31
GT200100016A (es) 2001-10-19
CN1395578A (zh) 2003-02-05
AP2002002586A0 (en) 2002-09-30
EE200200405A (et) 2003-12-15
WO2001055147A1 (en) 2001-08-02
KR20020065939A (ko) 2002-08-14
HN2001000013A (es) 2001-06-18
SK10632002A3 (sk) 2003-06-03
PA8510701A1 (es) 2002-12-11
PL356802A1 (en) 2004-07-12
NO20023527D0 (no) 2002-07-24

Similar Documents

Publication Publication Date Title
PE20011066A1 (es) PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS
PE20010211A1 (es) Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina
PE20040165A1 (es) Uso de analogos del benzimidazol en el tratamiento de la proliferacion celular
PE20011047A1 (es) Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas
PE20090279A1 (es) Derivados de 3,3-espiroindolinona como agentes antagonistas de mdm2
PE20060361A1 (es) Compuestos heterociclicos como inhibidores de la cinesina mitotica
PE20001485A1 (es) Derivados de la camptotecina que tienen actividad antitumoral
PE20020753A1 (es) Heteroaromaticos fusionados como activadores de la glucoquinasa
PE20020406A1 (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS 2,6-DISUSTITUIDAS COMO INHIBIDORES DE LAS PROTEINAS CINASAS
PE20020915A1 (es) Diaminotiazoles como inhibidores de quinasas dependientes de ciclina
DK0736039T3 (da) Forbindelser med væksthormon-frigivende egenskaber
PE20050525A1 (es) Derivados de pirazol sustituido y compuestos relacionados como antagonistas del receptor de bradiquinina b1
PE20050087A1 (es) Derivados de 2-oxodihidropiridina n-sustituidos
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
PE20020228A1 (es) Compuestos organicos como inhibidores de 3',5' guanosin monofosfato ciclico fosfodiesterasa
PE20000427A1 (es) Nuevas dihidropirimidinas
PE20000728A1 (es) Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
PE20030497A1 (es) Combinaciones de un inhibidor de pde 5 y otros agentes activos
PA8571001A1 (es) 2-(2,6-diclorofenil)-diarilimidazoles
PE20020589A1 (es) 5-espiropirimidin-2,4,6-triona como inhibidores de metaloproteinasas
CO5271675A1 (es) Derivados de decahidro-isoquinolinas, proceso para su preparacion, composicion y compuestos farmaceuticos que los contienen
PA8495101A1 (es) Derivados de 13-metileritromicina
PE20060504A1 (es) Derivados de pirimidina en el tratamiento de cancer
PE91598A1 (es) Pirroles sustituidos
BR0308145A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto

Legal Events

Date Code Title Description
FC Refusal